Previous Page  21 / 37 Next Page
Information
Show Menu
Previous Page 21 / 37 Next Page
Page Background

Page 75

Notes:

conferenceseries

.com

Volume 9, Issue 9 (Suppl)

J Cancer Sci Ther, an open access journal

ISSN: 1948-5956

World Cancer 2017

October 19-21, 2017

25

th

WORLD CANCER CONFERENCE

October 19-21, 2017 | Rome, Italy

Hexokinase 2 is a molecular bridge linking telomerase and autophagy

Jae-il Roh, Yujin Kim, Jahyun Oh, Yunmi Kim, Jihyun Lee

and

Han-Woong Lee

Yonsei University, South Korea

A

utophagy is systematically regulated by upstream factors and nutrients. Recent studies report that telomerase and

hexokinase 2 (HK2) regulate autophagy through mTOR and that telomerase has the capacity to bind to the HK2 promoter.

Here, we show that HK2 is a molecular bridge linking telomerase to autophagy. TERT-induced autophagy activation and its

further enhancement by glucose deprivation were suppressed by HK2 inhibition in HepG2 cells. The HK2 downstream factor

mTOR was responsible for TERT-induced autophagy activation under glucose deprivation, implying that TERT promotes

autophagy through a HK2-mTOR pathway. TERC played a similar role as TERT, and simultaneous expression of TERT and

TERC synergistically enhanced HK2 expression and autophagy. At the gene level, TERT bound to the HK2 promoter at a

specific region harboring the telomerase-responsive sequence TTGGG. Mutagenesis of TERC and the TERT-responsive

element on the HK2 promoter revealed that TERC is required for the binding of TERT to the HK2 promoter. We demonstrate

the existence of a telomerase-HK2-mTOR-autophagy axis and suggest that inhibition of the interaction between telomerase

and the HK2 promoter sensitizes cells to metabolic stress, and this pathway could be targeted for anti-cancer therapies.

Biography

Jae-il Roh has completed his PhD from Yonsei University and continuing his research at the same laboratory. He is working in Prof. Han-Woong Lee’s lab and

interested in mouse genetics, generation of mouse models, and cancer.

rohjaeil@gmail.com

Jae-il Roh et al., J Cancer Sci Ther 2017, 9:9(Suppl)

DOI: 10.4172/1948-5956-C1-112